MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

53.58 +1.06 (+2.02%)
Streaming Delayed Price Updated: 2:14 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
3 Unprofitable Stocks That Concern Us
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding... 
Via StockStory
News headline image
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea... 
Via StockStory
Topics Economy
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a... 
Via Finterra
Topics Initial Public Offering Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level... 
Via Finterra
Topics Intellectual Property
Tech Chips Lead Wall Street Rebound as Broadcom Crushes Estimates ↗
Via Chartmill
News headline image
Why Moderna (MRNA) Stock Is Trading Up Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 17.4% in the afternoon session after the company settled a long-running patent di... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
The news is likely to come as a relief to many investors, Citi told investors in a research note. 
Via Stocktwits
Topics Intellectual Property
Discover which S&P500 stocks are making waves on Wednesday. ↗
Via Chartmill
News headline image
2 High-Flying Stocks With More Upside to Buy and Hold ↗
It's not too late to get in on the action. 
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
Get insights into the top movers in the S&P500 index of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
MSTR, CRWD, MRNA, GTLB On Traders' Radar Today — Dow Futures Edge Higher As Investors Look Past Middle East Conflict ↗
Following warnings from Iran over the closure of the Strait of Hormuz, President Donald Trump announced that the U.S. would extend risk insurance for maritime trade through the strait. 
Via Stocktwits
Topics ETFs Government Intellectual Property
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines. 
Via Stocktwits
Topics Intellectual Property
News headline image
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Via ACCESS Newswire
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash ↗
Moderna stock has crashed 90% — but is the market mispricing what comes next? 7 key questions on MRNA's cancer vaccine, cash runway, and upside case. 
Via InvestorPlace
News headline image
The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines
As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of... 
Via Finterra
Topics Economy
News headline image
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
News headline image
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. ↗
The stock, after a few tough years, soared in the double-digits in January. 
Via The Motley Fool
News headline image
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors... 
Via StockStory
News headline image
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Moderna Stock Is Trading Higher Today: What's Going On? ↗
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating. 
Via Benzinga
News headline image
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear ↗
Moderna made a fortune with COVID vaccines, but revenue has since declined. 
Via The Motley Fool
News headline image
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January. ↗
Laffont's new addition may represent an exciting recovery story. 
Via The Motley Fool
Topics Artificial Intelligence
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story